Abstract
Objective To explore the diagnostic value of FTO combined with CEA or CYFRA21-1 for nonsmall cell lung cancer (NSCLC) and to provide a theoretical basis for molecular diagnosis of NSCLC. Methods Totally, 60 patients with nonsmall cell lung cancer (NSCLC) treated in our hospital between Feb. 2018 and Feb. 2019 were enrolled into the patient group (Pat group) and 50 healthy individuals with normal physical examination results in our hospital over the same time span into the control group (Con group). Serum of each participant was collected, and then qRT-PCR was adopted for quantification of serum FTO and the chemiluminescence method for quantification of serum CEA and CYFRA21-1. Additionally, corresponding ROC curves were drawn for diagnostic value analyses of FTO, CEA, and CYFRA21-1 in NSCLC and Cox regression analysis was performed for analysis of independent factors impacting the patients' 3-year prognosis. Results The Pat group presented notably higher FTO, CEA, and CYFRA21-1 levels than the Con group (all P < 0.05), and patients with a high FTO level faced notably higher probabilities of stage III + IV and lymph node metastasis (LNM) (both P < 0.05). Additionally, according to ROC curve-based analysis, with a high level in patients with NSCLC, FTO had high specificity and sensitivity in diagnosing NSCLC; joint detection of it with CEA or CYFRA21-1 demonstrated a higher sensitivity in NSCLC diagnosis and presented a higher specificity in diagnosing early NSCLC compared with detection of CEA or CYFRA21-1 alone. According to Cox regression analysis, clinical stage, LNM, and FTO were independent risk factors impacting the prognosis of patients with LC (all P < 0.05). Conclusion FTO presents a high level in NSCLC cases, and joint detection of it with CEA or CYFRA21-1 delivered a higher specificity in diagnosing NSCLC in contrast to detection of CEA or CYFRA21-1 alone, so the joint detection is worth popularizing in clinical scenarios.
Highlights
Lung cancer (LC) has always been intractable as a leading cause of death from cancer worldwide [1]
FTO presents a high level in nonsmall cell lung cancer (NSCLC) cases, and joint detection of it with CEA or CYFRA21-1 delivered a higher specificity in diagnosing NSCLC in contrast to detection of CEA or CYFRA21-1 alone, so the joint detection is worth popularizing in clinical scenarios
According to analysis of clinical stage, we discovered a certain value of FTO, CEA, and CYFRA21-1 in clinical staging of NSCLC
Summary
Lung cancer (LC) has always been intractable as a leading cause of death from cancer worldwide [1]. With a gradually growing incidence worldwide, it has ranked first among all kinds of male tumours in terms of incidence, and its incidence among females has been greatly rising [2]. The pathogenesis of NSCLC is still under exploration. Despite various treatments against NSCLC, such as surgery, chemotherapy, and radiotherapy [5], patients with it still suffer an unfavorable 5-year overall survival (OS) rate due to its late diagnosis and drug resistance to cytotoxicity and the absence of feasible and reliable biomarkers for its diagnosis as well as prognosis [6]. The identification of novel diagnostic biomarkers or therapeutic targets is paramount to the control of tumours
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
